- Home
- GMAB vs SQM Comparison
GMAB vs SQM Comparison
Compare GMAB & SQM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SQM
- Stock Information
- Founded
- GMAB 1999
- SQM 1968
- Country
- GMAB Denmark
- SQM Chile
- Employees
- GMAB N/A
- SQM N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SQM Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- GMAB Health Care
- SQM Industrials
- Exchange
- GMAB Nasdaq
- SQM Nasdaq
- Market Cap
- GMAB 12.1B
- SQM 11.3B
- IPO Year
- GMAB N/A
- SQM 1993
- Fundamental
- Price
- GMAB $24.14
- SQM $42.08
- Analyst Decision
- GMAB Buy
- SQM Hold
- Analyst Count
- GMAB 9
- SQM 8
- Target Price
- GMAB $40.71
- SQM $45.56
- AVG Volume (30 Days)
- GMAB 1.2M
- SQM 1.1M
- Earning Date
- GMAB 05-01-2025
- SQM 03-04-2025
- Dividend Yield
- GMAB N/A
- SQM 0.51%
- EPS Growth
- GMAB 83.82
- SQM N/A
- EPS
- GMAB 16.85
- SQM N/A
- Revenue
- GMAB $2,988,286,182.00
- SQM $4,528,761,000.00
- Revenue This Year
- GMAB $19.59
- SQM N/A
- Revenue Next Year
- GMAB $14.50
- SQM $31.37
- P/E Ratio
- GMAB $14.08
- SQM N/A
- Revenue Growth
- GMAB 30.67
- SQM N/A
- 52 Week Low
- GMAB $18.64
- SQM $32.24
- 52 Week High
- GMAB $31.88
- SQM $51.90
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- SQM 62.30
- Support Level
- GMAB $23.63
- SQM $37.31
- Resistance Level
- GMAB $24.11
- SQM $40.48
- Average True Range (ATR)
- GMAB 0.37
- SQM 1.37
- MACD
- GMAB 0.22
- SQM 0.28
- Stochastic Oscillator
- GMAB 93.88
- SQM 87.76
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SQM Sociedad Quimica y Minera S.A.
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM is developing a hard rock lithium project in Australia and expanding its lithium refining assets in China.